Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companiesSUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades of experience ...

Core Insights - CeriBell reported Q2 2025 revenue of $21.2 million, a 38.5% increase from $15.3 million in Q2 2024, surpassing analyst expectations of $20.45 million [1][2] - The company experienced a net loss of $13.6 million, widening from $8.9 million in Q2 2024, despite improvements in gross margin to 88% [1][2][8] Financial Performance - Revenue (GAAP) for Q2 2025 was $21.2 million, up 38.5% year-over-year from $15.3 million in Q2 2024 [2] - Earnings per share (EPS, GAAP) were $(0.38), better than the expected $(0.40) and a significant improvement from $(1.61) in Q2 2024, reflecting a 76.4% year-over-year change [2] - Gross margin improved to 88%, up from 86% in Q2 2024, attributed to a higher proportion of subscription revenue [2][6] - Operating expenses increased by 55.6% year-over-year to $33.6 million, primarily driven by sales and marketing costs [2][7] - The net loss widened to $13.6 million, compared to $8.9 million in Q2 2024, although the loss per share showed improvement [2][8] Business Model and Strategy - CeriBell's business model relies on recurring revenue from disposable headbands and subscription fees for its Clarity platform, which provides AI-driven seizure analysis [4] - The company aims to expand its customer base across acute care hospitals and broaden clinical indications for its technology, supported by FDA regulatory clearance [4][12] - As of Q2 2025, CeriBell had 584 active accounts, an increase from 558 at the end of Q1 2025, although the pace of new signings has slowed [5] Product and Market Expansion - The Ceribell System combines rapid EEG hardware with AI algorithms for real-time seizure detection, allowing non-specialists to monitor patients [3][10] - Clarity, the AI platform, recently received FDA clearance for pediatric use, although significant revenue from this segment is not expected until 2025 [11] - CeriBell serves approximately 3% of the U.S. market for rapid EEG monitoring, indicating substantial growth potential [12] Outlook and Guidance - Management raised the revenue outlook for full year 2025 to $85 million to $88 million, reflecting confidence in sustained growth and account expansion [14] - Gross margin is expected to remain in the mid-80% range, with strategies in place to mitigate potential tariff impacts [14][15]

SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 & Recent Highlights Reported total revenue of $21.2 million in the second quarter of 2025, a 38% increase compared to the same period in 2024Achieved gross margin of 88% in the second quarter ...

Company Overview - Ceribell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions [3] - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute care settings [3] - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3] - The system is FDA-cleared for detecting suspected seizure activity and is currently used in intensive care units and emergency rooms across the U.S. [3] Upcoming Event - Jane Chao, Ph.D., CEO and Co-founder of Ceribell, will present at the Canaccord Genuity 45 Annual Growth Conference [1] - The presentation is scheduled for Tuesday, August 12, 2025, at 11:00 a.m. Pacific Standard Time / 2:00 p.m. Eastern Standard Time [2] - A live and archived webcast of the presentation will be available on the Ceribell website [2]

Company Overview - CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions [3] - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute care settings [3] - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3] - The system is FDA 510(k) cleared for indicating suspected seizure activity and is currently used in intensive care units and emergency rooms across the U.S. [3] Financial Results Announcement - CeriBell will release its financial results for the second quarter of 2025 after the close of trading on August 5, 2025 [1] - A conference call to discuss the financial results will begin at 1:30 p.m. PT / 4:30 p.m. ET on the same day [1] Investor Information - Investors can listen to the conference call by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using access code 7468193 [2] - A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website [2]

Core Viewpoint - Ceribell, Inc. has filed complaints against Natus Medical Incorporated for patent infringement related to point-of-care EEG technology, seeking an investigation and exclusion order from the USITC to prevent the importation of infringing products [1][2]. Company Overview - Ceribell is a medical technology company focused on transforming the diagnosis and management of serious neurological conditions, having developed a novel point-of-care EEG platform [5][6]. - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions, and is FDA-cleared for indicating suspected seizure activity [5]. Legal Actions - Ceribell has filed a complaint with the U.S. International Trade Commission and the U.S. District Court in Delaware, alleging that Natus infringes on six of its patents related to EEG headband and electrode design [1][2]. - The company emphasizes its commitment to fair competition and the protection of its intellectual property to continue delivering innovative products [3].

Company Overview - Ceribell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions [3] - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute care settings [3] - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3] - The system is FDA-cleared for detecting suspected seizure activity and is currently used in intensive care units and emergency rooms across the U.S. [3] Upcoming Event - Jane Chao, Ph.D., CEO and Co-founder of Ceribell, will present at the William Blair 45 Annual Growth Stock Conference [1] - The presentation is scheduled for Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time [2] - A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website [2]

Core Insights - CeriBell, Inc. reported a strong financial performance for Q1 2025, with total revenue reaching $20.5 million, a 42% increase from $14.4 million in Q1 2024, driven by new account adoption and expansion within existing accounts [4][11] - The company is optimistic about continued growth in 2025, focusing on physician education and product development, including the introduction of a pediatric Clarity algorithm [3][8] Financial Performance - Total revenue for Q1 2025 was $20.5 million, up 42% from $14.4 million in Q1 2024, with product revenue at $15.6 million (41% increase) and subscription revenue at $4.9 million (45% increase) [4][15] - Gross profit for Q1 2025 was $18.0 million, with a gross margin of 88%, compared to $12.3 million and 86% in Q1 2024 [5][11] - Operating expenses increased by 55% to $32.2 million in Q1 2025, primarily due to investments in the commercial organization and increased headcount [6][11] - The net loss for Q1 2025 was $12.8 million, or $0.36 per share, compared to a net loss of $8.5 million, or $1.56 per share, in Q1 2024 [7][11] Future Outlook - CeriBell raised its revenue guidance for the full year 2025 to a range of $83 million to $87 million, indicating a growth of approximately 27% to 33% over the previous year [8] - The company ended Q1 2025 with 558 total active accounts and received FDA clearance for the expansion of its Clarity algorithm, marking a significant milestone [11][11] Company Overview - CeriBell is a medical technology company focused on transforming the diagnosis and management of serious neurological conditions through its innovative EEG platform [13]

Company Overview - CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions [3] - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute care settings [3] - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3] - The system is FDA 510(k) cleared for indicating suspected seizure activity and is currently used in intensive care units and emergency rooms across the U.S. [3] Upcoming Event - Jane Chao, Ph.D., CEO and Co-founder of CeriBell, will present at the Bank of America Securities 2025 Health Care Conference [1] - The presentation is scheduled for May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time [2] - A live and archived webcast of the presentation will be available on the CeriBell website [2]

Core Insights - Ceribell has achieved FedRAMP High authorization, allowing its EEG technology to be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, enhancing rapid diagnosis for patients at risk of non-convulsive seizures [1][4][5] Group 1: Company Achievements - Ceribell is one of only 51 companies in the U.S. to receive FedRAMP High authorization, a significant cybersecurity credential that indicates compliance with the highest federal security standards [1][6] - The company's EEG system is already operational in VA hospitals following its Authority to Operate (ATO) in 2024, and the new authorization facilitates broader implementation across federal healthcare agencies [2][4] Group 2: Technology and Innovation - The Ceribell System is designed for rapid setup and continuous brain monitoring, combining portable hardware with AI-powered algorithms for quick diagnosis and ongoing patient monitoring [9] - The system is FDA-cleared for indicating suspected seizure activity and is currently utilized in intensive care units and emergency rooms across the U.S. [9] Group 3: Security and Compliance - FedRAMP High authorization reflects Ceribell's commitment to information security, ensuring that sensitive patient data is protected through rigorous security measures [5][7] - Less than 15% of FedRAMP Authorized systems meet the High security standard, highlighting the significance of Ceribell's achievement in this area [6]